These include Hodgkin's lymphoma (130–132), where they are associated with shorter patient survival (133), SOCS1 deficiency in this disease correlated with hyperactivation of JAK2 and downstream STAT6 leading to excessive proliferation (134), with SOCS1 mutations synergizing with presumed gain-of-function STAT6 mutations (135). This evidence concerns the gene STAT6 and Hodgkins lymphoma.